elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
API & MCP
Pricing
Log in
Sign up
Home
/
Subjects
/
Erlotinib
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Erlotinib
RIS
0.001
(Research Intensity Score)
Papers
118
Top papers
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
2023 · 681 citations
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer
2024 · 151 citations
Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
2021 · 640 citations
Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer
2019 · 1112 citations
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial
2023 · 83 citations
Newest papers
Multifunctional Hybrid Nano-Platform for Co-Delivery of Erlotinib and Silibinin: A Nanotherapeutic Strategy Against Triple-Negative Breast Cancer
2026
Global pharmacovigilance analysis of dermatologic toxicity in EGFR-TKI–treated NSCLC: a cross-database real-world study
2026
Afatinib-Induced Acneiform Eruption in EGFR Exon 21 L858R-Mutant Stage IVA Lung Adenosquamous Carcinoma: Dermoscopy-Supported Diagnosis and Complete Resolution Fifteen Days After Drug Withdrawal
2026
Titanium dioxide nanoparticle-modified screen-printed electrode for erlotinib determination
2026
PandaMap: A Python Package for Comprehensive Visualization of Protein-Ligand Interaction Networks
2026
A sample from the 100 top papers behind Erlotinib.
Create a free account to browse them all →
Erlotinib's history
Research intensity over time
Explore Erlotinib's full history
Hover any year for its value and switch resolutions with a free account. Personal adds monthly detail and the historical-intensity (HRI) line.
Create a free account
Already have an account?
Log in
to explore the data.
Close ✕
Erlotinib's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link